

Figure 1.1




Figure 1.2




Figure 2.1




Figure 2.2





Figure 2.3

6/12


% M1  
(sub-G1)

11%




Untreated

16%


Lipofectamine  
alone

47%




DRIL32

51%




DRIL32-PEG

38%




DRIL16-PEG

18.5%



DRIL8-PEG

24.5%



DRIL32ss

Figure 3.1.




Figure 3.2




Figure 3.3




Figure 3.4

9/12




Figure 4

10/12




Figure 5.1





Figure 5.2

A



B




Figure 5.3.